SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death: Clarity and Consistency

J Am Coll Cardiol. 2023 Jun 27;81(25):2388-2390. doi: 10.1016/j.jacc.2023.04.035.

Authors

Stephen D Wiviott¹, David D Berg²

Affiliations

¹ TIMI (Thrombolysis In Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: swiviott@bwh.harvard.edu.
² TIMI (Thrombolysis In Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: https://twitter.com/ddbergMD.

PMID: 37344039
DOI: 10.1016/j.jacc.2023.04.035

No abstract available

Keywords: cardiovascular death; clinical trials; heart failure; meta-analysis; sodium-glucose cotransporter-2 inhibitors.

Publication types

Editorial
Comment

MeSH terms

Cardiovascular Diseases* / drug therapy
Cardiovascular System*
Heart Failure* / drug therapy
Hospitalization
Humans
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors